Staar Surgical Co Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
10analysts covering
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 11 Nov 2026 |
Monitoring Framework
Key Performance Indicators
EVO ICL Lenses Sold Globally (Cumulative) Quarterly4M
Quarterly Net Sales Quarterly93.5M
Gross Profit Margin Quarterly7,360.0%
Adjusted EBITDA Quarterly24.4M
Watch Items
- China Refractive Market Recovery and EVO+ Commercial LaunchTrigger: China net sales falling below $40 million per quarterAction: Re-evaluate commercial strategy, distributor inventory levels, and pricing models in the APAC region.
- U.S. Refractive Market Adoption and Surgeon TrainingTrigger: U.S. quarterly net sales dropping below $5 millionAction: Increase marketing spend, expand surgeon training programs, and leverage the FDA approval for patients aged 45 to 60.
- Permanent CEO AppointmentTrigger: Failure to appoint a permanent CEO by Q3 2026Action: Search Committee to accelerate engagement with executive search firms and evaluate internal/external candidates.
Research as of 19 Jun 2026